Inotiv Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 delivered strong DSA growth and margin improvement, offset by RMS weakness from lower NHP volumes. Cost reduction and site optimization efforts are underway, with innovation and new collaborations supporting future growth. No formal FY 2026 guidance was provided.
Fiscal Year 2025
-
Q4 and FY25 saw robust revenue and margin growth, led by DSA, despite a cybersecurity incident. RMS site consolidation and IT streamlining drove cost savings, while legal settlements and refinancing efforts improved the balance sheet. DSA demand and awards remain strong.
-
Q4 saw strong revenue and DSA award growth, with operational efficiencies from integration and site consolidation. Pricing has firmed, margins are improving, and NHP activity stabilized. Debt restructuring and cyber recovery efforts are ongoing, with systems fully restored.
-
Significant growth achieved through integration, operational optimization, and a focus on preclinical CRO services. Recent quarters saw strong DSA award growth and improved financial performance, with a clear path to long-term EBITDA targets. Customer-centric strategies and infrastructure investments underpin future expansion.
-
Integration of acquisitions and operational streamlining have stabilized the RMS business and driven strong growth in DSA, with high incremental margins and improved conversion rates. Market growth remains flat, with gains attributed to internal improvements and targeted investments. Regulatory and funding challenges are being managed, and capacity is sufficient for near-term growth.
-
Q3 2025 revenue grew 23.5% year-over-year to $130.7M, with improved margins and narrowed net loss. DSA and RMS segments both saw strong growth, while management remains cautious amid elevated cancellations and macroeconomic risks.
-
Bookings and margins are improving, led by Discovery and better client retention. RMS margins have rebounded, and NHP supply is stable but limited. Revenue and EBITDA growth depend on sustained momentum, while proactive lender engagement and balance sheet improvements are top near-term priorities.
-
Q2 FY2025 revenue rose 4.4% year-over-year to $124.3M, led by RMS growth from higher NHP sales, while DSA margins declined but quoting and awards activity was strong. Adjusted EBITDA improved to $8M, and a revised RMS optimization plan is expected to deliver higher savings sooner.
-
Q1 FY2025 revenue declined 11.5% year-over-year due to lower NHP pricing, with net loss widening to $27.6 million. Liquidity improved via a $27.5 million equity raise, and cost-saving initiatives are underway. Management expects revenue and margin growth for the rest of FY2025.
Fiscal Year 2024
-
Q4 2024 revenue rose 23% sequentially but fell 7.3% year-over-year, with margin pressure from high-cost NHP inventory. Management expects improved RMS margins and growth in 2025, driven by stronger NHP pre-sales and recurring services, though industry price pressures persist.
-
Revenue and margins declined sharply year-over-year due to lower NHP sales and pricing, but operational improvements, legal resolutions, and early signs of NHP market recovery position the company for a stronger Q4 and improved 2025 outlook.
-
Integration of acquisitions and new service launches have driven strong DSA growth, with new offerings now contributing up to 10% of sales. NHP supply has stabilized, but customer overbuying led to excess inventory and a shift toward long-term contracts. Small animal demand is down, but pricing remains stable.